Company news

Entrada Therapeutics, Inc. news in 2026

Entrada Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Entrada Therapeutics Reports Third Quarter 2026 Financial Results

November 5, 2026

Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer

October 21, 2026

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45

October 14, 2026

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

October 14, 2026

Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program

September 10, 2026

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

August 5, 2026

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

June 2, 2026

Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study

May 7, 2026

Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026

May 6, 2026

Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

February 25, 2026

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

February 17, 2026

Entrada Therapeutics to Present at Upcoming Investor Conferences

February 4, 2026

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

January 8, 2026

Decks in 2026